New antibiotics are at the forefront of one of the most critical battles in modern medicine as they promise hope against the rising tide of drug-resistant infections.Kinvard Bio, a Harvard startup, is pioneering a new class of these powerful drugs that specifically target bacterial ribosomes, an essential component of bacterial life.